The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Fructose-1,6-bisphosphatase opposes renal carcinoma progression
Open accessAbstract
Clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, is characterized by elevated glycogen levels and fat deposition. These consistent metabolic alterations are associated with normoxic stabilization of hypoxia-inducible factors (HIFs) secondary to von Hippel-Lindau (VHL) mutations that occur in over 90% of ccRCC tumours. However, kidney-specific VHL deletion in mice fails to elicit ccRCC-specific metabolic phenotypes and tumour formation, suggesting that additional mechanisms are essential. Recent large-scale sequencing analyses revealed the loss of several chromatin remodelling enzymes in a subset of ccRCC (these included polybromo-1, SET domain containing 2 and BRCA1-associated protein-1, among others), indicating that epigenetic perturbations are probably important contributors to the natural history of this disease. Here we used an integrative approach comprising pan-metabolomic profiling and metabolic gene set analysis and determined that the gluconeogenic enzyme fructose-1,6-bisphosphatase 1 (FBP1) is uniformly depleted in over six hundred ccRCC tumours examined. Notably, the human FBP1 locus resides on chromosome 9q22, the loss of which is associated with poor prognosis for ccRCC patients. Our data further indicate that FBP1 inhibits ccRCC progression through two distinct mechanisms. First, FBP1 antagonizes glycolytic flux in renal tubular epithelial cells, the presumptive ccRCC cell of origin, thereby inhibiting a potential Warburg effect. Second, in pVHL (the protein encoded by the VHL gene)-deficient ccRCC cells, FBP1 restrains cell proliferation, glycolysis and the pentose phosphate pathway in a catalytic-activity-independent manner, by inhibiting nuclear HIF function via direct interaction with the HIF inhibitory domain. This unique dual function of the FBP1 protein explains its ubiquitous loss in ccRCC, distinguishing FBP1 from previously identified tumour suppressors that are not consistently mutated in all tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hypoxia can provide energy to tumor cells by activating transcriptional programs that induce glucose uptake and glycolysis.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380
Self-citationReductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Self-citationFunctional genomics reveal that the serine synthesis pathway is essential in breast cancer
Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.-K., Jang, H. G., Jha, A. K., et al. (2011) · Nature · doi:10.1038/nature10350 · Cited by 1,683
Rini, B. I., Campbell, S. C., & Escudier, B. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60229-4 · Cited by 1,634
Cohen, H. T., & McGovern, F. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043172 · Cited by 1,591
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Varela, I., Tarpey, P. S., Raine, K. M., Huang, D., Ong, C. K., Stephens, P., Davies, H. R., Jones, D., Lin, M., Teague, J. W., et al. (2011) · Nature · doi:10.1038/nature09639 · Cited by 1,302
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 550
Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015)
Ban, H. S., Uto, Y., Won, M., & Nakamura, H. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1146252 · Cited by 45
Cell-to-cell lactate shuttle operates in heart and is important in age-related heart failure
Gizak, A., McCubrey, J. A., & Rakus, D. (2020) · Aging · doi:10.18632/aging.102818 · Cited by 44
Xing, Q., Zeng, T., Liu, S., Cheng, H., Ma, L., & Wang, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08111-0 · Cited by 44
Zhang, P., Shao, Y., Fang, Q., Liu, L., & Yang, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119840 · Cited by 44
Gu, L., Zhu, Y., Watari, K., Lee, M., Liu, J., Perez, S., Thai, M., Mayfield, J. E., Zhang, B., Rocha, K. C. E., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.03.021 · Cited by 43
Self-citationAnalyzing Tumor Metabolism In Vivo
Faubert, B., & DeBerardinis, R. J. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-121954 · Cited by 44
Kürschner, G., Zhang, Q., Clima, R., Xiao, Y., Busch, J. F., Kilic, E., Jung, K., Berndt, N., Bulik, S., Holzhütter, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22413 · Cited by 45
Wang, B., Fan, P., Zhao, J., Wu, H., Jin, X., & Wu, H. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0888-y · Cited by 43
Liao, K. L., Deng, S., Xu, L., Pan, W., Yang, S., Zheng, F., Wu, X., Hu, H., Liu, Z., Luo, J., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2060 · Cited by 44
Self-citationASS1 and ASL suppress growth in clear cell renal cell carcinoma via altered nitrogen metabolism
Khare, S., Kim, L. C., Lobel, G. P., Doulias, P., Ischiropoulos, H., Nissim, I., Keith, B., & Simon, M. C. (2021) · Cancer & Metabolism · doi:10.1186/s40170-021-00271-8 · Cited by 43
Self-citationSanders, E. B., & Diehl, S. (2015) · Oncoscience · doi:10.18632/oncoscience.128 · Cited by 43
Liu, M., Pan, Q., Xiao, R., Yu, Y., Lu, W., & Wang, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-67760-6 · Cited by 42
Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas
Haake, S. M., Weyandt, J. D., & Rathmell, W. K. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0115 · Cited by 41
Ran, H., Kong, S., Zhang, S., Cheng, J., Zhou, C., He, B., Xin, Q., Lydon, J. P., DeMayo, F. J., Feng, G., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700978114 · Cited by 41
Li, J., Wang, Y., Li, Q., Xue, J.-J., Wang, Z., Yuan, X., Tong, J., & Xu, L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167857 · Cited by 40
RetractedSun, C., Zhao, C., Li, S., Wang, J., Zhou, Q., Sun, J., Ding, Q., Liu, M., & Ding, G. (2018) · Journal of Cancer · doi:10.7150/jca.26275 · Cited by 41
How DNA methylation affects the Warburg effect
Zhu, X., Xuan, Z., Chen, J., Li, Z., Zheng, S., & Song, P. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.45420 · Cited by 42
Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity
Wang, B., Zhou, Y., Zhang, J., Jin, X., Wu, H., & Huang, H. (2019) · Theranostics · doi:10.7150/thno.38137 · Cited by 39
Brown, B. A., Myers, P. J., Adair, S. J., Pitarresi, J. R., Sah‐Teli, S. K., Campbell, L. A., Hart, W. S., Barbeau, M. C., Leong, K. M., Seyler, N. M., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-22-2945 · Cited by 40
Self-citationMetabolic Regulation of Epithelial to Mesenchymal Transition: Implications for Endocrine Cancer
Bhattacharya, D., & Scimè, A. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00773 · Cited by 39
Guo, T., Chen, T., Gu, C., Li, B., & Xu, C. (2015) · Tumor Biology · doi:10.1007/s13277-015-3463-6 · Cited by 41
Self-citationFBP1 modulates cell metabolism of breast cancer cells by inhibiting the expression of HIF-1α
Shi, L., He, C., Li, Z., Wang, Z., & Zhang, Q. (2017) · Neoplasma · doi:10.4149/neo_2017_407 · Cited by 39
Fructose-1,6-Bisphosphatase 1 Reduces18F FDG Uptake in Hepatocellular Carcinoma
Chen, R., Li, J., Zhou, X., Liu, J., & Huang, G. (2017) · Radiology · doi:10.1148/radiol.2017161607 · Cited by 38
Fructose-1,6-bisphosphatase is a novel regulator of Wnt/β-Catenin pathway in breast cancer
Li, K., Ying, M., Feng, D., Du, J., Chen, S., Dan, B., Wang, C., & Wang, Y. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.10.050 · Cited by 37
Olcina, M. M., Balanis, N. G., Kim, R. K., Aksoy, B. A., Kodysh, J., Thompson, M. J., Hammerbacher, J., Graeber, T. G., & Giaccia, A. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.093 · Cited by 39
Gizak, A., Duda, P., Wiśniewski, J., & Rakus, D. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.03.001 · Cited by 38
Zhai, X., Yang, R., Chu, Q., Guo, Z., Hou, P., Li, X., Bai, C., Lu, Z., Qiao, L., Fu, Y., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-024-01549-x · Cited by 36
Self-citationModulating NK cell metabolism for cancer immunotherapy
Terrén, I., Orrantia, A., Vitallé, J., Astarloa-Pando, G., Zenarruzabeitia, O., & Borrego, F. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.10.003 · Cited by 39
Möck, A., Zschäbitz, S., Kirsten, R., Scheffler, M., Wolf, B., Herold‐Mende, C. C., Kramer, R., Busch, E., Jenzer, M., Jäger, D., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02428-3 · Cited by 35
Tuerhong, A., Xu, J., Shi, S., Tan, Z., Meng, Q., Hua, J., Liu, J., Zhang, B., Wang, W., Yu, X., et al. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03866-y · Cited by 35
Tracing Renal Cell Carcinomas back to the Nephron
Lindgren, D., Sjölund, J., & Axelson, H. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.05.003 · Cited by 40
Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma
Gutteridge, R. E. A., Singh, C. K., Ndiaye, M. A., & Ahmad, N. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.02.013 · Cited by 34
Fructose and Mannose in Inborn Errors of Metabolism and Cancer
Lieu, E. L., Kelekar, N., Bhalla, P., & Kim, J. (2021) · Metabolites · doi:10.3390/metabo11080479 · Cited by 36
Huang, Y., Xu, Y., Song, R., Ni, S., Liu, J., Xu, Y., Ren, Y., Rao, L., Wang, Y., Wei, L., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00699 · Cited by 33
Peng, M., Li, S., He, Q., Zhao, J., Li, L., & Ma, H. (2018) · BMC Genomics · doi:10.1186/s12864-017-4427-6 · Cited by 33
Role of Bicaudal C1 in renal gluconeogenesis and its novel interaction with the CTLH complex
Leal-Esteban, L. C., Rothé, B., Fortier, S., Isenschmid, M., & Constam, D. B. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007487 · Cited by 33
van den Heuvel, C. N. A. M., van Ewijk, A., Zeelen, C., de Bitter, T. J. J., Huynen, M. A., Mulders, P., Oosterwijk, E., & Leenders, W. P. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00117 · Cited by 33
Metabolic Anti-Cancer Effects of Melatonin: Clinically Relevant Prospects
Samec, M., Líšková, A., Koklesová, L., Zhai, K., Varghese, E., Samuel, S. M., Šudomová, M., Lučanský, V., Kassayová, M., Péč, M. J., et al. (2021) · Cancers · doi:10.3390/cancers13123018 · Cited by 33
Zhang, K., Hast, M. W., Izumi, S., Usami, Y., Shetye, S. S., Akabudike, N. M., Philp, N. J., Iwamoto, M., Nissim, I., Soslowsky, L. J., et al. (2018) · The American Journal of Sports Medicine · doi:10.1177/0363546518778789 · Cited by 32
Self-citationNicotinamide N-Methyltransferase: An Emerging Protagonist in Cancer Macro(r)evolution
Parsons, R. B., & Facey, P. D. (2021) · Biomolecules · doi:10.3390/biom11101418 · Cited by 34
Knott, M. E., & Minatta, J. N. (2016) · Journal of Molecular Biomarkers & Diagnosis · doi:10.4172/2155-9929.s2-015 · Cited by 32
Ortmayr, K., Charwat, V., Kasper, C., Hann, S., & Koellensperger, G. (2016) · The Analyst · doi:10.1039/c6an01342b · Cited by 32
Novel insight into the Warburg effect: Sweet temptation
Zhang, H., Liu, S., Fu, S., Zhao, Q., Wang, Y., Yuan, Y., & Zhang, C. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104844 · Cited by 33
Lü, C., Ren, C., Yang, T., Sun, Y., Qiao, P., Wang, D., Lv, S., & Yu, Z. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0842 · Cited by 31
Lin, M., Fang, Y., Li, Z., Li, Y., Feng, X., Zhan, Y., Xie, Y., Liu, Y. S., Liu, Z., Li, G., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01306-z · Cited by 31
Liu, Z., You, Y., Chen, Q., Li, G., Pan, W., Yang, Q., Dong, J., Wu, Y., Bei, J., Pan, C., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.07.015 · Cited by 32
Self-citationZhu, H., Yu, H. T., Zhou, H., Zhu, W., & Wang, X. (2023) · Advanced Science · doi:10.1002/advs.202205818 · Cited by 30
Oxygen gradient and tumor heterogeneity: The chronicle of a toxic relationship
Pandkar, M. R., Dhamdhere, S. G., & Shukla, S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188553 · Cited by 33
1H NMR metabolomics analysis of renal cell carcinoma cells: Effect of VHL inactivation on metabolism
Čuperlović‐Culf, M., Cormier, K., Touaibia, M., Reyjal, J., Robichaud, S., Belbraouet, M., & Turcotte, S. (2015) · International Journal of Cancer · doi:10.1002/ijc.29947 · Cited by 31
HSF2 regulates aerobic glycolysis by suppression of FBP1 in hepatocellular carcinoma.
Yang, L., Ning, Z., Wang, L., Xia, Y., & Meng, Z. (2019) · PubMed Central · Cited by 30
Li, J., Zhang, Q., Guan, Y., Liao, D., Jiang, D., Xiong, H., Zhan, H., & Pang, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04863-0 · Cited by 29
Dai, T., Rosario, S. R., Katsuta, E., Dessai, A. S., Paterson, E. J., Novickis, A. T., Gomez, E. C., Zhu, B., Liu, S., Wang, H., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111756 · Cited by 29
Significance of Methylation of FBP1 Gene in Non-Small Cell Lung Cancer
Dong, Y., Huaying, S., Wan, D., Chihong, Z., Ruibin, J., Xiaojiang, S., & Feng, J. (2018) · BioMed Research International · doi:10.1155/2018/3726091 · Cited by 29
Hung, Y.-H., Huang, H.-L., Chen, W.-C., Yen, M., Cho, C.-Y., Weng, T., Wang, C., Chen, Y., Chen, L., & Lai, M.-D. (2016) · Oncology Reports · doi:10.3892/or.2016.5334 · Cited by 28
Zou, J., Zhu, X., Xiang, D., Zhang, Y., Li, J., Su, Z., Kong, L., & Zhang, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.005 · Cited by 28
Hu, J., Wang, J., Li, C., & Shang, Y. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16439 · Cited by 28
Cheng, X. C., Zhang, B., Guo, F., Wu, H., & Jin, X. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13149 · Cited by 28
Yu, C., Huang, W., Zhou, Z., Liang, S., Zhou, Z., Liu, J., Zhao, H., Liu, L., Dong, H., Zou, F., et al. (2019) · Respiratory Research · doi:10.1186/s12931-022-01979-x · Cited by 28
Popławski, P., Tohge, T., Bogusławska, J., Rybicka, B., Tański, Z., Treviño, V., Fernie, A. R., & Piekiełko‐Witkowska, A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.12.011 · Cited by 28
Associations among Metabolism, Circadian Rhythm and Age-Associated Diseases
Cao, Y., & Wang, R.-H. (2017) · Aging and Disease · doi:10.14336/ad.2016.1101 · Cited by 28
Ahmad, A., Paffrath, V., Clima, R., Busch, J. F., Rabien, A., Kilic, E., Villegas, S. L., Timmermann, B., Attimonelli, M., Jung, K., et al. (2019) · Cancers · doi:10.3390/cancers11091298 · Cited by 28
Duda, P., Janczara, J., McCubrey, J. A., Gizak, A., & Rakus, D. (2020) · Cells · doi:10.3390/cells9010205 · Cited by 28
Zhang, P., Yang, J. H., Liu, X., Huang, C., Tao, Y., Shen, P., Bai, Z., Xiao, C., Zhou, L., Li, G., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06706-6 · Cited by 29
Brooks, S. A., Khandani, A. H., Fielding, J. R., Lin, W., Sills, T., Lee, Y. Z., Arreola, A., Milowsky, M. I., Wallen, E., Woods, M. E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2115 · Cited by 27
Metabolic landscapes in sarcomas
MIALLOT, R., Galland, F., Millet, V., Blay, J., & Naquet, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01125-y · Cited by 29
Tumor immunotherapy: Mechanisms and clinical applications
Nong, C., Guan, P., Li, L., Zhang, H., & Hu, H. (2022) · MedComm – Oncology · doi:10.1002/mog2.8 · Cited by 27
Treating liver cancer through arginine depletion
Prasad, Y. R., Anakha, J., & Pande, A. H. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103940 · Cited by 27
Genomic Copy Number Alterations in Renal Cell Carcinoma with Sarcomatoid Features
Ito, T. K., Pei, J., Dulaimi, E., Menges, C. W., Abbosh, P. H., Smaldone, M. C., Chen, D. Y. T., Greenberg, R. E., Kutikov, A., Viterbo, R., et al. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.10.180 · Cited by 27
Knott, M. E., Manzi, M., Zabalegui, N., Salazar, M. O., Puricelli, L., & Monge, M. E. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00538 · Cited by 27
Lü, C., Ren, C., Yang, T., Sun, Y., Qiao, P., Han, X., & Yu, Z. (2020) · Theranostics · doi:10.7150/thno.46861 · Cited by 26
Gu, Y.-R., Kim, J., Na, J. C., & Han, W. K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269432 · Cited by 26
Xu, Y., Xia, D., Huang, K., & Liang, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04872-x · Cited by 26
Schab, A. M., Greenwade, M. M., Stock, E. C., Lomonosova, E., Cho, K., Grither, W. R., Noia, H. M., Wilke, D., Mullen, M. M., Hagemann, A. R., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-0347 · Cited by 26
Riscal, R., Gardner, S. M., Coffey, N. J., Carens, M., Mesaros, C., Xu, J. P., Xue, Y., Davis, L., Demczyszyn, S. M., Vogt, A. D., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-0821 · Cited by 25
Self-citationFan, Z., Zheng, W., Li, H., Wu, W., Liu, X., Sun, Z., Hu, H., Du, L., Jia, Q., & Liu, Q. (2020) · Oncology Reports · doi:10.3892/or.2020.7541 · Cited by 25
Xiao, Y., Rabien, A., Buschow, R., Amtislavskiy, V., Busch, J. F., Kilic, E., Villegas, S. L., Timmermann, B., Schütte, M., Mielke, T., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1998 · Cited by 25
Fructose-1,6-bisphosphatase 1 dephosphorylates and inhibits TERT for tumor suppression
Li, M., Wang, Z., Tao, J., Jiang, H., Huang, Y., Guo, D. S., Zhao, H. C., He, X., Luo, S., Jiang, X., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01597-2 · Cited by 24
The von Hippel–Lindau Tumor Suppressor Protein
Kaelin, W. G. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050527 · Cited by 24
Xu, F. L., Ke, X., Hong, M., Huang, M., Chen, C., Tian, X., Hang, H., & Chu, J. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.01.024 · Cited by 24
Todd, V. M., Vecchi, L. A., Clements, M. E., Snow, K. P., Ontko, C. D., Himmel, L. E., Pinelli, C. J., Rafat, M., & Johnson, R. W. (2021) · Communications Biology · doi:10.1038/s42003-021-02648-3 · Cited by 25
Immunometabolic coevolution defines unique microenvironmental niches in ccRCC
Tang, C., Xie, A. X., Liu, E., Kuo, F., Kim, M., Dinatale, R., Golkaram, M., Chen, Y.-B., Gupta, S., Motzer, R., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.06.005 · Cited by 25
Šoltýsová, A., Breza, J., Jr., Takáčová, M., Feruszová, J., Hudecová, S., NOVOTNA, B., Rozborilova, E., Pastoreková, S., Kádaši, Ľ., & Križanová, O. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3014 · Cited by 24
Association between FBP1 and hypoxia-related gene expression in clear cell renal cell carcinoma
Ning, X., Teng, L., Gong, Y., He, Q., SHEN, Q., Peng, S., Wang, J., CHEN, J.-C., Guo, Y., & Gong, K. (2016) · Oncology Letters · doi:10.3892/ol.2016.4504 · Cited by 24
Anticancer natural products targeting immune checkpoint protein network
Chun, K., Kim, D., Raut, P. K., & Surh, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.11.006 · Cited by 24
Invalidation of mitophagy by FBP1-mediated repression promotes apoptosis in breast cancer
Liu, Y., Jiang, Y., Wang, N., Jin, Q., Ji, F., Zhong, C., Zhang, Z., Yang, J., Ye, X., & Chen, T. (2017) · Tumor Biology · doi:10.1177/1010428317708779 · Cited by 24
Wattanavanitchakorn, S., Rojvirat, P., Chavalit, T., MacDonald, M. J., & Jitrapakdee, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194252 · Cited by 23
Knockdown of FBP1 enhances radiosensitivity in prostate cancer cells by activating autophagy
Li, X. R., Zhou, K., Yin, Z., Gao, Y., & Yang, X. (2020) · Neoplasma · doi:10.4149/neo_2020_190807n728 · Cited by 23
TYROBP is a potential prognostic biomarker of clear cell renal cell carcinoma
Wu, P., Xiang, T., Wang, J., Lv, R., & Wu, G. (2020) · FEBS Open Bio · doi:10.1002/2211-5463.12993 · Cited by 23
Molecular and Metabolic Subtypes in Sporadic and Inherited Clear Cell Renal Cell Carcinoma
Czyzyk-Krzeska, M., Figueroa, J. A. L., Gulati, S., Cunningham, J. T., Meller, J., Shamsaei, B., Vemuri, B., & Plas, D. R. (2021) · Genes · doi:10.3390/genes12030388 · Cited by 23
Reprogramming of glycolysis by chemical carcinogens during tumor development
D’Souza, L. C., Shekher, A., Challagundla, K. B., Sharma, A., & Gupta, S. C. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.10.004 · Cited by 22
Abbott, K. L., Ali, A., Reinfeld, B. I., Deik, A., Subudhi, S., Landis, M. D., Hongo, R. A., Young, K. L., Kunchok, T., Nabel, C. S., et al. (2024) · eLife · doi:10.7554/elife.95652 · Cited by 22
A Mathematical Model for Enzyme Clustering in Glucose Metabolism
Jeon, M., Kang, H.-W., & An, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-20348-7 · Cited by 22
Wang, J., Wu, Q., & Qiu, J. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0203-3 · Cited by 22
PTEN loss promotes Warburg effect and prostate cancer cell growth by inducing FBP1 degradation
Song, C., Zhang, J., Liu, X., Li, M., Wang, D., Kang, Z., Yu, J., Chen, J., Pan, H., Wang, H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.911466 · Cited by 21
Zhang, Y., Zhu, J., Sun, H., & Li, J. (2022) · Applied Materials Today · doi:10.1016/j.apmt.2022.101687 · Cited by 21
p62 functions as a signal hub in metal carcinogenesis
Zhang, Z., & Costa, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.014 · Cited by 21
Wang, Y., Zheng, X., Zhu, G., Li, N., Zhou, C., Yang, C., & Zeng, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.861328 · Cited by 20
Tian, T., Li, J., Shi, D., Zeng, Y.-P., Yu, B., Li, X., Wei, P., & Zhou, X. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05208-7 · Cited by 20
He, T., Wang, Y., Lv, W., Wang, Y., Li, X., Zhang, Q., Shen, H., & Hu, J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05138-x · Cited by 20
DiNatale, R. G., Sánchez, A., Hakimi, A. A., & Reznik, E. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.04.028 · Cited by 20
Metadata
- Authors
- Li, B., Qiu, B., Lee, D. S. M., Walton, Z. E., Ochocki, J. D., Mathew, L. K., Mancuso, A., Gade, T. P. F., Keith, B., Nissim, I., & Simon, M. C.
- Affiliations
- Abramson Cancer Center (US)
- Howard Hughes Medical Institute (US)
- University of Pennsylvania (US)
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Simon, M. Celeste
- ORCID
- Venue
- Nature
- Published
- 2014-07-20
- Volume
- 513
- Issue
- 7517
- Pages
- 251-255
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4162811
- OpenAlex
- W2069663698
- Cited by
- 535
- References
- 31
- Citations by year
- 2026: 24 · 2025: 38 · 2024: 44 · 2023: 44 · 2022: 48 · 2021: 64 · 2020: 54 · 2019: 42 · 2018: 54 · 2017: 42 · 2016: 40 · 2015: 33 · 2014: 6
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- National Cancer Institute (F30CA177106, P01CA104838, CA104838, F32CA192758, P30CA016520)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK053761, DK-053761, R56DK053761)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- FBP1, clear cell renal cell carcinoma, von Hippel-Lindau protein, hypoxia-inducible factor, glycolysis, pentose phosphate pathway, Warburg effect, renal tubular epithelial cells, tumor progression, chromatin remodeling, cancer metabolism, epigenetic regulation, gluconeogenesis
- MeSH terms
- Animals, Carcinoma, Renal Cell, Cell Line, Epithelial Cells, Glycolysis, Fructose-Bisphosphatase, Humans, Kidney Neoplasms, Models, Molecular, NADP, Swine, Protein Structure, Tertiary, Disease Progression, Cell Line, Tumor, Cell Proliferation, Basic Helix-Loop-Helix Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
